Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes.

Area of Science:

• Nanomedicine
• Biotechnology
• Oncology

Background:

• Magnetoliposomes (MLs) are promising for cancer imaging and therapy.
• Targeting MLs to tumor-specific markers enhances drug delivery.
• The αvβ3 integrin is overexpressed on tumor neovascularization and certain cancer cells.

Purpose of the Study:

• To evaluate MLs functionalized with cyclic Arginine-Glycine-Aspartate (cRGD) for targeting αvβ3 integrin.
• To assess the potential of cRGD-MLs in ovarian cancer (SKOV-3) and glioma models.
• To visualize and quantify ML uptake in vivo and ex vivo using MRI and fluorescence imaging.

Main Methods:

• Produced cRGD-functionalized MLs (cRGD-MLs) and anionic MLs with Texas Red.
• Injected SKOV-3 cells into Swiss nude mice and allowed tumor growth.
• Administered MLs and tracked biodistribution using preclinical MRI and fluorescence imaging (FLI) at various time points.
• Confirmed intratumoral uptake via ex vivo FLI, EPR spectroscopy, and histology.

Main Results:

• cRGD-MLs showed significantly higher tumor uptake than control anionic MLs in SKOV-3 xenografts, visualized by MRI and FLI.
• MRI detected maximal ML uptake at 4 hours, while FLI indicated peak uptake at 24 hours.
• Ex vivo analyses confirmed maximal tumoral ML uptake at 4 hours, with iron particles identified in xenografts.

Conclusions:

• cRGD-MLs are effectively visualized in tumors using both MRI and FLI, with MRI offering higher sensitivity.
• The study confirms that cRGD-MLs can target SKOV-3 xenografts in mice.
• These findings support the further development of cRGD-MLs as theranostic agents for cancer.